Presentation of. Burgdorf, 1 st November 2012
|
|
- Poppy Newman
- 5 years ago
- Views:
Transcription
1 Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012
2 Important Notice The information contained in this document has not been independently verified and no representation or warranty, express or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. None of Ypsomed Holding AG, its advisors or representatives, or their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as may, plans, expects, believes and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements. 2 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
3 Agenda 1. Introduction 2. Finances 3. Operating activities 4. Outlook 5. Questions and answers 3 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
4 The first half of the 2012/13 business year at a glance (1/2) Sales and EBIT have been dominated by the discontinuation of the OptiSet and OptiPen Pro for Sanofi. It was not possible to fully offset the year-on-year decline in sales of these products, which amounted to some CHF 14.0 million. In the Diabetes Direct business, the sales growth of over 75% enjoyed by the mylife OmniPod is very pleasing. Sales for the whole segment are up some CHF 6.0 million (16%). Ypsomed s Ypsotec subsidiary, which h manufactures mechanical precision i parts, posted an operating loss of some CHF 0.8 million, thus adversely affecting the Others segment result. Thanks to rigorous cost management, Ypsomed is turning a profit, generating EBIT of CHF 2.4 million (previous year: CHF 3.0 million). 4 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
5 The first half of the 2012/13 business year at a glance (2/2) Ypsomed invested a total of CHF 8.1 million in fixed assets, with a large proportion of these investments being made in expanding pen needle production facilities in Switzerland. Overall, Ypsomed spent CHF 10.2 million on R&D. Investing in developing proprietary products has a long-term focus and lays the foundations for the future success of the Ypsomed Group. Major shareholder h Willy Michel has extended d his commitment by a further three years (until March 2017) as he firmly believes in Ypsomed s strategy and future prospects. The shareholders approved the authorized capital increase in June. Ypsomed is continuing to investigate a range of synergy-boosting investment opportunities but has yet to reach any concrete decisions. 5 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
6 Key figures In million CHF 1 st HY 2012/13 1 st HY 2011/12 Delta in % Sales of goods and services % thereof Delivery Devices % thereof Diabetes Direct Business % thereof Other % Gross profit % Gross profit in % 22.8% 23.2% 2% Operating profit % Operating profit in % 2.0% 2.4% Net profit % Net profit in % 1.7% 6.2% Research and development expenditures, total % Investments in fixed assets % Equity ratio in % 63.6% 66.6% Employee headcount (per ) 1'020 1' % 6 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
7 Developments in the Diabetes Care segment The mylife OmniPod enjoyed sales growth of over 75% in the period under review. The second generation of the product will be launched in the UK, the Netherlands, Germany, Switzerland and Austria by the end of Sales also commenced in Norway and Sweden following a long licensing process. The new mylife Unio blood glucose monitoring system was presented at the leading European Diabetes Congress (EASD) in Berlin and will be launched in early The market launch for mylife DailyDose has begun. This unique supplementary product for diabetics taking insulin is proving very popular. Production of mylife Orbit infusion sets was transferred as planned in the first half of the 2012/13 business year. The sets are now produced in the OmniGroup s factories in Queretaro, Mexico. Work to develop Ypsomed s own insulin pump remains on track, with the launch planned for Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
8 Developments in the Delivery Systems segment The award-winning winning ServoPen is turning into a real star of the YDS Custom Products range. Two new customers in Asia have been acquired for this highquality reusable insulin pen. Ypsomed has a number of finjection system projects in the pipeline and dis very confident that they will come to fruition thanks to the company s own excellent platforms. 8 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
9 Agenda 1. Introduction 2. Finances 3. Operating activities 4. Outlook 5. Questions and answers 9 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
10 The fall in sales is primarily due to OptiSet manufacturing being discontinued In million CHF 2012/ /12 Δ in % Delivery Devices % Diabetes Direct Business % Other % 42% Sales of goods and services % The Delivery Devices segment comprises the product groups pen systems, pen needles and other injection moulds produced by Ypsomed. The Diabetes Direct Business segment covers the direct trade in a range of diabetes products, including sales of mylife Pura blood glucose monitoring systems, mylife Roto infusion sets and mylife OmniPod insulin patch pumps. Other contains the precision-turned parts business segment and currently unused real estate for operational purposes. 10 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
11 Rigorous cost management safeguards profitability In million CHF 2012/13 in % 2011/12 in % Sales of goods and services % % Cost of goods and services sold % % Gross profit % % 2% Marketing and sales expenses % % Administration expenses % % Other operating income % % Other operating expenses % % Operating profit % % The move to discontinue production of the successful OptiSet and OptiPen Pro has affected the gross profit margin. New products have not yet managed to fully offset the difference. Continued rigorous cost management, new products and projects will help improve the gross profit margin in the second half of the year. 11 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
12 Overview of EBIT by segment In million CHF 2012/ /12 Δ in % Delivery Devices % Diabetes Direct Business % Other Operating profit % With sales growth in excess of 75%, the mylife OmniPod made a key contribution to offsetting losses in the Diabetes Direct business. Ypsotec, which manufactures mechanical precision parts, faced significant pressure on its margins in the period under review and posted a loss of CHF 0.8 million. 12 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
13 EBITDA margin slightly below previous year s figure In million CHF 2012/13 in % 2011/12 in % Δ in % Operating profit % % -0.4% Depreciation of fixed assets % % 0.3% Amortisation of intangible assets % % -0.7% EBITDA % % -0.6% 13 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
14 Neutral financial result in the first half of the 2012/13 business year In million CHF 2012/13 in % 2011/12 in % Δ in % Operating profit % % -0.4% Financial income % % -5.4% Financial expenses % % 0.9% Profit before income taxes % % -5.0% Income taxes % % 0.5% Net profit % % -4.5% Earnings per share (basic and diluted) in CHF Financial income in the previous year included CHF 5.1 million in profits from the sale of non-current financial assets. 14 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
15 Robust and streamlined balance-sheet structure In million CHF in % in % Assets Cash and cash equivalents % % Trade receivables % 8.9% % 7.5% Other current assets % % Prepayments and accrued income % % Current income taxes % % Inventories % % Customer machinery % % Total current assets % % Financial i assets % 2.7% % 2.8% Deferred income tax assets % % Fixed assets % % Intangible assets % % Total non-current assets % % Total assets % % 15 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
16 Equity ratio at 63.6% In million CHF in % in % Liabilities and equity Financial liabilities % % Current financial liabilities to major shareholder % 1.5% % Trade payables % % Prepayments from customers % % Current income tax payable % % Other payables % 0.7% % 0.8% Accrued liabilities and deferred income % % Provisions % % Total current liabilities % % Non-current liabilities to major shareholder % % Other non-current financial liabilities % % Provisions % % Deferred income tax liabilities % 0.2% % 0.2% Total non-current liabilities % % Total equity % % Total liabilities and equity % % 16 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
17 Ypsomed investing in Switzerland In million CHF 2012/ /12 Cashflow from operating activities Purchases of financial assets Disposal of financial assets Purchases of fixed assets Disposal of fixed assets Purchases of intangible assets Final payment acquisition Cashflow from investing activities Repayment of financial liabilities to major shareholder Proceeds from borrowings Cost due to approved increase in share capital Distribution of capital reserves Purchase of treasury shares Cashflow from financing activities Effect of foreign currency translation Total Cashflow Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
18 Agenda 1. Introduction 2. Finances 3. Operating activities 4. Outlook 5. Questions and answers 18 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
19 The YDS Delivery Systems umbrella brand creates clarity and has been well received by the industry 19 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
20 More confidence. More success. With Ypsomed Delivery Systems. Custom products Contract development Contract manufacturing Drug & device assembly More information on Ypsomed AG // Brunnmattstrasse 6 // 3401 Burgdorf T // F //
21 Big Pharma sees strong growth, particularly in Asia and Latin America 21 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
22 Large number of biosimilars in developing countries 1 many of which will require a pen Source: Datamonitor, October Developing countries = not the EU, not the US, not Japan 22 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
23 ServoPen more customers using the same platform 23 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
24 YpsoPen Twist in industrialization phase - the first deliveries planned for the second quarter of Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
25 Sanofi pens OptiSet, OptiPen Pro and components for Solostar 25 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
26 First three autoinjector projects secured thanks to YpsoMate additional autoinjector versions now available 26 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
27 Diabetes Care our direct business 27 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
28 More Freedom. More Confidence. With mylife. Blood glucose monitoring systems Pen needles and safety pen needles Infusion systems Accessories and services More information at Ypsomed AG // Brunnmattstrasse 6 // 3401 Burgdorf // Switzerland T // F //
29 Proportion of overweight individuals in the adult population Source: UBS / Chart: FuW, si 29 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
30 Standing out from the competition as a full-range supplier with an excellent knowledge of the market Diabetes is spreading rapidly (the WHO predicts there will be some 440 million diabetics by 2030) making it a market worth billions and with high potential for growth. On the other hand, healthcare costs in conjunction with diabetes are increasing, i putting pressure on suppliers costs. As a comprehensive provider of products to treat diabetes, Ypsomed has a wide range of opportunities i in this regard with various different product and price strategies. The key to success in this area of business is a knowledge of individual healthcare markets. Ypsomed has a global network of subsidiaries and distributors as well as the necessary expertise. 30 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
31 Pen needles mylife Clickfine 4 mm (32G) At the EASD Congress, Ypsomed unveiled the thinnest, most precise Ypsomed needle yet: 32G corresponds to a diameter of 0.23 mm (standard pen needles have a diameter of 31G - 29G, or mm). Ypsomed has succeeded d in winning i a major US-based customer, who will begin marketing Clickfine pen needles under its own brand in the first half of Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
32 Blood glucose monitoring new mylife Unio The target group includes Type 1 diabetics and, generally, people who monitor their blood glucose very frequently. The next generation of blood glucose monitoring systems based on customer surveys and focus groups. The new blood glucose monitoring system appeals thanks to its userfi friendliness. New standards being set in terms of accurate measurements. 32 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
33 Infusion systems the next-generation mylife OmniPod receives CE accreditation! 33 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
34 Infusion systems the new mylife OmniPod is now much smaller and more lightweight 35% smaller 16% thinner 25% lighter only 25 grams! 34 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
35 Infusion systems Ypsomed s Lanzi pump project is on track for market launch in the second half of 2014 Ypsomed s s insulin pump stands out thanks to its compact size, ease of operation and the use of pre-filled ampules 35 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
36 Infusion systems Lanzi can be priced more competitively, which will expand its market 36 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
37 Infusion systems mylife Orbit as a generic infusion set and an infusion set for Lanzi 37 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
38 New mylife DailyDose micro-syringe The self-injection system in credit card format consists of three small syringes that are pre-filled with the daily insulin requirement. Ypsomed currently distributes mylife DailyDose in Switzerland, Germany, the UK, Norway, Austria and the Netherlands. 38 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
39 Agenda 1. Introduction 2. Finances 3. Operating activities 4. Outlook 5. Questions and answers 39 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
40 Outlook for the 2012/13 business year Despite a slight dip in sales, we are expecting to match last year s operating profit in the 2012/13 business year. 40 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
41 Key dates Presentation of the annual results for 2012/13 May 28, General Meeting of Shareholders June 26, Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
42 Agenda 1. Introduction 2. Finances 3. Operating activities 4. Outlook 5. Questions and answers 42 Ypsomed Holding AG Presentation of Semi-Annual Results 2012/13
43 Questions and answers
Annual Figures 2017/18. Burgdorf, 24 May 2018
Annual Figures 2017/18 Burgdorf, 24 May 2018 Important information The information contained in this document has not been verified by an independent source. It should be taken with caution and no assurance
More informationYpsomed Holding AG Semiannual Report 2012/13
Ypsomed Holding AG Semiannual Report 2012/13 Ypsomed key figures at a glance In thousand CHF April 1, 2012 April 1, 2011 Sept. 30, 2012 Sept. 30, 2011 Change in % Sales of goods and services 119 745 122
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationYpsomed Holding Ag Semiannual report 2009/10
Ypsomed Holding Ag Semiannual report 2009/10 Key figures at a glance in thousand CHF April 1, 2009 Sept. 30, 2009 April 1, 2008 Sept. 30, 2008 Change in % Sales of goods and services 126 775 139 458 12
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationYpsomed Holding AG Annual Report 2011/12
Ypsomed Holding AG Annual Report 2011/12 Ypsomed Holding AG Annual Report 2011/12 Ypsomed Better Life All over the world, there are many people who live their lives independently and with great enjoyment
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationYpsomed Holding AG Semiannual Report 2018 / 19
Ypsomed Holding AG Semiannual Report 2018 / 19 The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationYpsomed Holding AG Annual Report 2012/13
Ypsomed Holding AG Annual Report 2012/13 Ypsomed Holding AG Annual Report 2012/13 Ypsomed Better Life Giving patients the opportunity to treat and control their illnesses themselves in order to lead independent
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationYpsomed Holding AG Annual Report 2015 / 16
Ypsomed Holding AG Annual Report 2015 / 16 The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationThe more question you ask the more different answers you will get
The more question you ask the more different answers you will get Experience and lessons learned in China Ulrike Bauer Cicor Innovation Insights Symposium Kloten, September 27, 2016 Agenda Introduction
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More informationSummary Statement of Financial Position (consolidated)
2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,
More informationPhotoCure ASA. Presentation. Results 1 Quarter 2004
PhotoCure ASA Presentation Results 1 Quarter 2004 7 th of May 2004 Progress towards sustained profitability Continued product roll out Metvix European sales continue to grow Final US approval for Actinic
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationYpsomed Holding AG Annual Report 2014 / 15
Ypsomed Holding AG Annual Report 2014 / 15 Ypsomed Holding AG Annual Report 2014 / 15 3 4 Ypsomed Annual Report Contents 6 Key figures 8 Letter to shareholders 11 How the unpegging of the Swiss Franc
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationSWEDISH MATCH RESULTS PRESENTATION Q3 2017
SWEDISH MATCH RESULTS PRESENTATION Q3 2017 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationSWEDISH MATCH RESULTS PRESENTATION Q4 2018
SWEDISH MATCH RESULTS PRESENTATION Q4 2018 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,
More informationQ2 INVESTOR KIT JANUARY-JUNE 2011
Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationPRESENTATION ON 2017 THIRD QUARTERLY RESULTS
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationYpsomed Holding AG Annual Report 2013/14
Ypsomed Holding AG Annual Report 2013/14 Ypsomed Holding AG Annual Report 2013/14 Ypsomed Better Life More freedom, more confidence: before patients all over the world can experience these benefits for
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More information1Q 2015 Results A Positive Start to 2015
1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationZealand Pharma A/S Interim report for Q (un-audited)
Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationAN INTRODUCTION TO YPSODOSE FOR THE LARGE-VOLUME INJECTION OF BIOLOGICS
AN INTRODUCTION TO YPSODOSE FOR THE LARGE-VOLUME INJECTION OF BIOLOGICS In this article Ian Thompson, Vice-President Business Development at Ypsomed, describes self-injection device trends for larger injection
More informationQ4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
More informationDynamic Growth. Investora Gerhard Mahrle CFO COLTENE Holding AG. September 2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. Investora 2018 Dynamic Growth Gerhard Mahrle CFO COLTENE Holding AG September 2018 COLTENE AN INTERNATIONALLY
More informationASL MARINE. DBS Vickers Pulse of Asia Roadshow 10 January 2012
ASL MARINE DBS Vickers Pulse of Asia Roadshow 10 January 2012 Presentation Outline Group Overview 1Q FY2012 Financial Review (3 months ended 30 September 2011) Operations Review - Shipbuilding - Shiprepair
More informationLetter to Shareholders SEMI-ANNUAL REPORT 2008
Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into
More informationSMARTPILOT FOR YPSOMATE: TRANSFORMING A PROVEN AUTOINJECTOR INTO A FULLY CONNECTED DEVICE
SMARTPILOT FOR YPSOMATE: TRANSFORMING A PROVEN AUTOINJECTOR INTO A FULLY CONNECTED DEVICE In this article, Orfeo Niedermann, Business Development Director, Ypsomed Delivery Systems, provides insights into
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationCompany overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
More informationWntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationQ Investor Kit January December 2015
Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This
More informationDEVELOPMENT OF PLATFORM INJECTION DEVICES ADDRESSING HUMAN FACTORS AT AN EARLY STAGE FOR DIFFERENT USER GROUPS
DEVELOPMENT OF PLATFORM INJECTION DEVICES ADDRESSING HUMAN FACTORS AT AN EARLY STAGE FOR DIFFERENT USER GROUPS In this article Orfeo Niedermann, Business Development Director, and Jakob Lange, PhD, Account
More informationThromboGenics Business Update H1 2018
Press release 6 September 2018 Regulated Information ThromboGenics Business Update H1 2018 Positive Topline Results for Diabetic Eye Disease Portfolio Shareholder approval for company name change to Oxurion
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationKAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO
KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,
More informationInvestor Relations 1Q 2017
Investor Relations 1Q 2017 History Leading Authentic Sports Brand Inspired by the Style, Elegance and Passion of our Italian Heritage Founded by FILA brothers in Biella, Italy Established FILA Korea FILA
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More informationForward Looking Statements
Therapeutic products for respiratory diseases September 2008 Forward Looking Statements This presentation may contain forward-looking statements that are based on management s current expectations and
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationFirst Quarter Results to March 31, Shire plc April 25, 2008
First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationDISCLOSEABLE AND CONNECTED TRANSACTION AND PROPOSED APPOINTMENT OF CHIEF EXECUTIVE OFFICER
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationSecond Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1
Second Quarter and First Half 2011 Conference Call 29 July, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including
More informationTotal Face Group Limited
Total Face Group Limited 2017 Half Year Results Presentation Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position
More informationHUMAN FACTORS ENGINEERING OF SELF-INJECTION DEVICES
HUMAN FACTORS ENGINEERING OF SELF-INJECTION DEVICES In this overview, Tobias Nemeth, Business Development Manager, Ypsomed Delivery Systems, provides a useful insight into human factors engineering. The
More informationBusiness Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd.
Business Results for the First Quarter of FY216/3 August 4, 215 (Tue.) NH Foods Ltd. Contents Contents I. Consolidated Business Results for FY216/3 1Q (Apr. Jun.) II. Outlook for FY216/3 III. Consolidated
More informationFIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO
FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More information